Tradestie Institutional Equity Comparison Engine

REGN vs UNOV โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

REGN Overall Edge

REGN Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Regeneron Pharmaceuticals Inc (REGN) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, REGN trades at 15.3x Forward P/E with 30.4% operating margin (+36.3% YoY revenue) versus UNOV at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, REGN sits in BREAKOUT (6th %ile IV; Dealer Gamma Walls on Pro) against UNOV sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner REGN
REGN 15.3x vs UNOV N/M Fwd P/E
Growth & Margin Winner REGN
Op Margin 30.4% vs N/A ยท YoY +36.3% vs N/A
Momentum & Technical Winner REGN
1Y +37.0% vs +9.5% ยท 52W Pos 90% vs 84%
Options & Structure Winner REGN
BREAKOUT (6th %ile IV) vs UNCLASSIFIED (N/A IV)
REGN NASDAQ
Regeneron Pharmaceuticals Inc
Pharmaceutical Preparations
$952.40
-0.32% 1D
Market Cap $98.8B
1M Return +20.44%
1Y Return +37.04%
Forward P/E 15.3x
Unified AI Score
38.6 / 100 SELL
Tech 23.0 Fund 43.0 Flow 67.0 Mom 41.1
UNOV Cboe BZX
Innovator U.S. Equity Ultra Buffer ETF - November
Pharmaceutical Preparations
$41.13
-0.95% 1D
Market Cap N/A
1M Return -0.97%
1Y Return +9.53%
Forward P/E N/M
Unified AI Score
58.7 / 100 HOLD
Tech 48.0 Fund 60.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: REGN +37.04% UNOV +9.53% Spread: +27.51 pp (REGN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
REGN TTM Op. Margin: 30.4% UNOV TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on REGN vs UNOV. Trailing 12-month operating profitability (REGN 30.4% vs UNOV N/A) and valuation multiples (REGN 15.3x vs UNOV N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: REGN (8) vs UNOV (2)
Institutional Metric REGN UNOV Criterion Row Winner
Market Capitalization Scale $98.8B N/A Larger Scale REGN
Trailing P/E Ratio Valuation 21.1x N/M Lower Multiple REGN
Forward P/E Ratio Valuation 15.3x N/M Lower Multiple REGN
Revenue Growth (YoY) Growth +36.3% N/A Higher Growth REGN
Operating Margin (TTM) Profitability 30.4% N/A Higher Margin REGN
Net Profit Margin Profitability 28.5% N/A Higher Margin REGN
Return on Equity (ROE) Capital Efficiency 14.9% N/A Higher ROE REGN
52-Week Range Position Momentum 90% ($592โ€“$992) 84% ($37โ€“$42) Stronger Trend REGN
Beta / 30D Volatility Risk Regime 0.33ฮฒ ยท 55% Vol 0.46ฮฒ ยท 11% Vol Lower Realized Risk UNOV
Unified Institutional Score Composite Signal 38.6 / 100 (SELL) 58.7 / 100 (HOLD) Higher Composite UNOV

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full REGN vs UNOV Buy Guide
REGN BREAKOUT
52d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live REGN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
UNOV UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live UNOV Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither REGN nor UNOV registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.